default author photo

Filippo Pietrantonio

Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology

Italy

SCHOLARLY PAPERS

7

DOWNLOADS

453

TOTAL CITATIONS

14

Scholarly Papers (7)

1.

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

Number of pages: 126 Posted: 16 Nov 2019
University of Pisa - Department of Oncology, University of Pisa - Department of Oncology, University of Pisa - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, ARNAS Garibaldi Catania, Fondazione IRCCS Casa Sollievo della Sofferenza, Ospedale degli Infermi, University Campus Biomedico, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), University of Pisa - Department of Oncology, F. Spaziani Hospital, Università degli Studi di Udine, Fondazione Poliambulanza, Istituto Oncologico Veneto – IRCCS, S. Croce and Carle Teaching Hospital, Government of the Italian Republic (Italy) - National Cancer Institute, University of Pisa - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, ARNAS Garibaldi Catania, Careggi University Hospital of Florence, University of Messina, University of Pisa - Department of Oncology, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, General Hospital, Prato, University of Naples Federico II, Ente Ospedaliero Ospedali Galliera, AOU Città della Salute e della Scienza di Torino, Massa Carrara, University of Rome Tor Vergata, Azienda Toscana Nord Ovest, IRCCS Ospedale San Martino IST, Candiolo Cancer Institute, Ospedale Santa Maria della Misericordia, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, University of Pisa, University of Pisa, Careggi University Hospital of Florence, University of Pisa - Department of Oncology and affiliation not provided to SSRN
Downloads 189 (409,459)
Citation 14

Abstract:

Loading...

2.

Atypical RAS Mutations in Metastatic Colorectal Cancer

Number of pages: 31 Posted: 13 Apr 2019
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Memorial Sloan Kettering Cancer Center - Department of Medicine, Foundation Medicine, Inc., Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda Ospedaliera-Universitaria Pisana, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Foundation Medicine Inc., National Cancer Center Hospital East, Foundation Medicine Inc., Sungkyunkwan University - Department of Medicine, Catholic University of Milan - Fondazione Policlinico Universitario Agostino Gemelli, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Azienda Ospedaliera-Universitaria Pisana, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Foundation Medicine, Inc., Foundation Medicine Inc., Sungkyunkwan University - Division of Hematology-Oncology, National Cancer Center Hospital East, University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department, University of Pisa - Department of Oncology, Memorial Sloan Kettering Cancer Center - Department of Pathology and University of Pisa - Department of Oncology
Downloads 100 (689,572)

Abstract:

Loading...

colorectal cancer; RAS mutations; atypical; anti-EGFR treatment; tumor mutational burden

Association between sex and response to encorafenib-based combinations in BRAF V600E mutant metastatic colorectal cancer

Number of pages: 52 Posted: 24 Nov 2025
affiliation not provided to SSRN, Vall d'Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Institute of Oncology (VHIO), affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Medical Oncology 1, Fondazione Policlinico Universitario A. Gemelli IRCCS - Oncologia Medica, University Hospital of Pisa - Unit of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - Department of Medical Oncology, Careggi University Hospital of Florence - Clinical Oncology Unit, Ospedale Santa Chiara - Azienda Ospedaliero Universitaria Pisana, AUSL Romagna - Oncology Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, University Hospital of Pisa - Unit of Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO)Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)
Downloads 29 (1,400,723)

Abstract:

Loading...

BRAF mutation, colorectal cancer, Biomarker, sex, MEK inhibitor, binimetinib

4.

First-Line Panitumumab Plus FOLFOX-4 Followed by Maintenance Therapy with Single-Agent Panitumumab or Panitumumab Plus 5-FU/LV in Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Valentino Study

Number of pages: 107 Posted: 05 Oct 2018
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pisa - Department of Oncology, Humanitas University - Clinical and Research Center, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Grande Ospedale Metropolitano Niguarda, University of Turin, Azienda Ospedaliero-Universitaria Careggi, Ente Ospedaliero Ospedali Galliera, University of Messina, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori, Humanitas University, Università degli Studi di Genova, Fondazione Poliambulanza, University of Messina, University of Messina, Azienda Socio Sanitaria Territoriale Lariana, Azienda Socio Sanitaria Territoriale Bergamo Ovest, Azienda Ospedaliera San Gerardo, Ospedale Antonio Perrino, University of Pisa - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department
Downloads 54 (1,041,696)

Abstract:

Loading...

colorectal cancer; maintenance treatment; panitumumab; RAS wild-type; randomised trial

5.

Prognostic Impact of the Braf V600e Mutation in Patients with Msi-High Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors

Number of pages: 29 Posted: 29 Apr 2025
affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), University of Toulouse - Hospital Rangueil, University of Toulouse - Hospital Rangueil, University of Texas at Houston - MD Anderson Cancer Center, Mayo Clinic, Université de Montpellier - Institut de Recherche en Cancérologie de Montpellier, University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, Vall d’Hebron Institute of Oncology (VHIO), University of Bordeaux - Institut Bergonié, University Hospital of Pisa - Unit of Medical Oncology, Gustave Roussy, University of Lille - CHU Lille, affiliation not provided to SSRN, CHU Rouen, CHU Poitiers, affiliation not provided to SSRN, City of Hope, affiliation not provided to SSRN, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Université Paris Cité and Université de Poitiers - Gastroenterology Department
Downloads 49 (1,074,648)

Abstract:

Loading...

Colorectal cancer, BRAF mutation, microsatellite instability, immune checkpoint inhibitor

6.

Braf + Egfr +/- Mek Inhibitors after Immune Checkpoint Inhibitors In Braf V600e Mutated and Deficient Mismatch Repair or Microsatellite Instability High Metastatic Colorectal Cancer

Number of pages: 23 Posted: 26 Jun 2024
Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Université de Poitiers - Gastroenterology Department, Charité–Universitätsmedizin Berlin, University of Toulouse - Hospital Rangueil, University of Texas at Houston - MD Anderson Cancer Center, University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, Institut d’Hématologie et d’Oncologie Pédiatrique (iHOPe) - Centre Léon Bérard, affiliation not provided to SSRN, University of Toulouse - Hospital Rangueil, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, University of Bordeaux - Institut Bergonié, Mayo Clinic, Vall d’Hebron Institute of Oncology (VHIO), University of Lille - CHU Lille, University Hospital of Pisa - Unit of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), affiliation not provided to SSRN and Université Paris Cité
Downloads 20 (1,448,301)

Abstract:

Loading...

Metastatic colorectal cancer, BRAF mutation, microsatellite instability high, deficient mismatch repair, immune checkpoint inhibitors, encorafenib, cetuximab

7.

Durable responses to immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients with poor performance status

Number of pages: 11 Posted: 04 Mar 2026
Sheba Medical Center, Sheba Medical Center, University of Pennsylvania, Sheba Medical Center, University of Texas at Houston - MD Anderson Cancer Center, Sorbonne University, University of Texas at Houston - MD Anderson Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Medical Oncology and Sheba Medical Center
Downloads 12 (1,548,648)

Abstract:

Loading...

colorectal cancer, immunotherapy, performance status, MSI-high, dMMR